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MANAGEMENT: THE FRENCH EXAMPLE 
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Pierre Fabre SA, Boulogne Billancourt, France
OBJECTIVE: Homeopathy is based on the principle of
similitude, using at non-toxic doses, in a sick patient,
medicinal substances of mineral, plant or animal origin,
which, at toxic doses, are capable of triggering in healthy
individuals a range of symptoms similar to those observed
during the disease under consideration. Homeopathy is
mainly employed in cases of ENT disease, anxiety disor-
ders and sleep disorders. Today, in France, about 2 in
every 10 physicians prescribe frequently or regularly 
some sort of homeopathic-based treatment. METHOD:
hOMEO is a longitudinal, prospective, observational
programme. Three hundred patients with rhinitis chronic,
treated either by homeopathic (HM) or allopathic man-
agement (AM), will be followed during 6 months. In this
study, the level of resources used and patient satisfaction
will be collected in order to provide conﬁrmation of the
economic relevance of reliance on homeopathic manage-
ment versus allopathic management. RESULTS: At in-
clusion time, both groups expressed the same level of
symptoms. There are no differences neither in the number
nor in the type of symptoms due to their rhinitis chronic.
Three months later, the chronic rhinitis symptoms are
resorbed within the same proportion for both groups.
None symptoms have been better or badly resorbed the
one than the other. At 3 months, the SF-12 score on the
physical dimension are the following HM 51.8, AM 47.9
(p < 0.05), the inclusion score being comparable between
the two groups at inclusion induced that patients treated
by a homeopathic management improved their QoL on
this dimension. The quarterly cost of care for patients
treated with allopathic management (€45.74) is 30%
more expensive than the quarterly cost of care for patients
treated with homeopathic management (€27). This dif-
ference is essentially due to a higher frequency of consul-
tations and a more expensive mean medical prescription
with the allopathic management. CONCLUSION:
Reliance on homeopathic management appears to give
rise to an annual reimbursement cost, which is half that
induced by allopathic general practitioners.
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OBJECTIVES: Care of patients with acute respiratory
distress syndrome (ARDS) is challenging and costly.
Administering muscle relaxants may facilitate mechanical
ventilation and improve oxygenation. After the relaxant
is discontinued, some patients have delayed recovery 
of neuromuscular function, while other patients develop
prolonged muscle weakness—acute quadriplegic myopa-
thy syndrome (MYOPATHY). The objective of this study
was to examine the incremental cost-effectiveness ratio
(ICER) of cisatracurium versus using a traditional steroid
based agent—vecuronium. METHODS: We designed a
Markov ICER computer model. The base case involved a
55-year-old man admitted to the ICU for ARDS and then
paralyzed for 3.5 days. Patients were modeled to be in
one of the following health states: ICU-intubated, ICU-
extubated, hospital ward, long-term care, home, or death.
Patient progression was divided into 3.5 day cycles over
six months. One trial found the average recovery after
cisatracurium to be one hour versus 6 hours with vecuro-
nium. Approximately 27% of ICU patients paralyzed 
for 3.5 days would be expected to develop MYOPATHY
within 7 days. However, it is not evident that
cisatracurium reduces this incidence. RESULTS: Our
modeling predicted the total cost for an ARDS patient to
be $58,629. At 6 months: mortality = 43%, patients dis-
charged home = 32%, in-hospital = 8%, and long term
care facility = 17%. Using average wholesale prices,
cisatracurium costs $599 for 3.5 days, versus $332 for
vecuronium. The modeling suggests that cisatracurium is
cost-effective (the ICER is < $35,000/QALY) if intubation
time is reduced by 7%, or if ICU extubated time is
reduced by 1.8%, or if the time the patient is in the ward
is reduced by 2.3%. CONCLUSIONS: Incremental costs
for cisatracurium are a very small portion of the total cost
of care for ARDS patients. If cisatracurium use leads to
very small reductions in ICU time, or ward length, it
becomes a cost-effective intervention.
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OBJECTIVES: There is growing recognition of the public
health challenge posed by treating persons with chronic
obstructive pulmonary disease (COPD). Although treat-
ment options are limited, observational studies have
shown that long-acting beta agonists (LABA) and/or
inhaled corticosteroids (ICS) may prolong survival. We
investigated the cost-effectiveness of competing strategies
for treating COPD. METHODS: Subject-level cost and
